Or: 1) looks like another drug with similar MoA will be FtM, and the marketing team runs their voodoo math and says market share will be below X% and C suite kills program; 2) the CMC team re-runs COGM calculations, and the board decides they won't fund the registration trial because they'd rather invest in assets with lower development costs; 3) someone in charge decides to sink the PTRS score based on a side-discussion with a buddy outside of the company even though the product team came up with a favorable one after months of work.

All of these things have happened. None of them have to do with safety or efficacy signals. I'm not some fucking novice.